Esther is co-founder of NEUROSERVICE and Head of the Multi-Electrode Array (MEA) laboratory. Esther has managed NEUROSERVICE’s MEA laboratory since its inception and has more than 15 year of experience in electrophysiology. Esther was trained in biochemistry and cellular engineering (Ms Science) and earned her PhD in Neuroscience from the University of Marseille.
Prior joining NEUROSERVICE, she worked at TROPHOS, a drug discovery company focused on neurodegenerative diseases. There, she designed and optimized cell-based screenings and documented the effect of Lead compounds using molecular biology and electrophysiological recordings in acute brain slices.
At NEUROSERVICE, Esther designed and managed hundreds of studies for biotech and pharmaceutical companies. Esther excels in the development and standardization of new MEA-based assays to document the pharmacological profile of compounds in development and document their mechanism of action.
My name is Esther Steidl, I earned my PhD in Neuroscience under the supervision of Dominique Debanne in Marseille. I am a co-founder of Neuroservice and I manage the MEA laboratory since 2007. I have more than 15 years of experience in Electrophysiology and I focus entirely on the use of the MEA technique.
The beauty of this technique is that you can see anything occurring at the neuronal network level in a context that is very close to the physiological conditions. In addition, this technique is non-invasive, and allows you to answer pharmacological questions very precisely as the compounds effects are averaged from a very large number of neurons that are recorded all at the same time.
I am particularly proud of the level of expertise we have reached during all those years working with pharmaceutical and biotech companies. The team has made amazing progress in developing new and sophisticated assays. We design completely customized studies that provide straightforward answers to our clients, helping them to make the best decision. The entire team is very proud to help push forward the development of compounds that might be tomorrow’s medicine, as efficient drugs are still lacking for many pathologies.
Being part of Neuroservices-Alliance is a unique opportunity to put the results obtained using different approaches into a wider perspective. Combining data from different assays performed by different experts in their field is really synergistic: it’s more than just adding data, it brings additional insights to the whole project and solidifies the drugs in development in an unparalleled way.